Life sciences company focusing on developing and advancing medicines that leverage psychedelics compounds MYND Life Sciences (CSE: MYND) (OTC: MYNDF) revealed that it’s now eligible for Depository Trust Company (DTS) services in relation to the company’s listing on the over-the-counter markets.
Listing on the OTC markets has its benefits as through it, investors from the United States will be able to easily trade the MYNDF stock as well as the MYND stock listed on the Canadian Securities Exchange (CSE).
DTC is a subsidiary of the Depository Trust and Clearing Corporation (DTCC), which is one of the largest securities depositories around the world that manage the electronic clearing and settlement of publicly traded companies.
Going forward, MYND is now eligible to be electronically cleared and settled, this will straighten the process of trading, enhance liquidity and provide direct access to investors in the U.S OTC capital markets.
“We are excited to receive DTC eligibility, which not only provides the Company with access to a broader range of US-based investors but also provides additional opportunities for investors in the US to acquire MYND shares. There are 300 million persons world-wide suffering from major depressive disorder and other related conditions who have not been well-served by the existing class of SSRIs to treat depression. We are convinced we have the scientific capacity, the intellectual property and the right leadership to achieve the first substantive innovation in this drug class in a generation,” said MYND’s CEO, Dr. Lyle Oberg.
